Abstract

Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K

Renin-angiotensin-aldosterone systems play a major role in the regulation of human homeostasis mechanism, which are also involved in the development of hypertension and end-organ damage through activation of angiotensin II. Inhibitors of the renin-angiotensin-aldosterone system may reduce the development of end-organ damage to a greater extent than other antihypertensive agents. Aliskiren is the first member of the new class of orally active direct renin inhibitors recently approved by the US Food and Drug Administration for the treatment of hypertension. Aliskiren directly inhibiting the renin and reducing the formation of angiotensin II, which is the most effective mediator involved in the pathogenesis of cardiovascular diseases. The present review mainly focuses on the pharmacodynamics and pharmacokinetics and clinical aspects of aliskiren. In this respect, the review will improve the basic idea to understand the pharmacology of aliskiren, which is useful for the further research in cardiovascular disease.

How to Cite this Article

Pubmed Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. Aliskiren: A Novel, Orally Active Renin Inhibitor. SRP. 2010; 1(1): 93-98. doi:10.4103/0975-8453.59518 Web Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. Aliskiren: A Novel, Orally Active Renin Inhibitor. http://www.sysrevpharm.org/?mno=302644636 [Access: March 28, 2021]. doi:10.4103/0975-8453.59518 AMA (American Medical Association) Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. Aliskiren: A Novel, Orally Active Renin Inhibitor. SRP. 2010; 1(1): 93-98. doi:10.4103/0975-8453.59518 Vancouver/ICMJE Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. Aliskiren: A Novel, Orally Active Renin Inhibitor. SRP. (2010), [cited March 28, 2021]; 1(1): 93-98. doi:10.4103/0975-8453.59518 Harvard Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K (2010) Aliskiren: A Novel, Orally Active Renin Inhibitor. SRP, 1 (1), 93-98. doi:10.4103/0975-8453.59518 Turabian Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. 2010. Aliskiren: A Novel, Orally Active Renin Inhibitor. Systematic Reviews in Pharmacy, 1 (1), 93-98. doi:10.4103/0975-8453.59518 Chicago Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. "Aliskiren: A Novel, Orally Active Renin Inhibitor." Systematic Reviews in Pharmacy 1 (2010), 93-98. doi:10.4103/0975-8453.59518 MLA (The Modern Language Association) Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K. "Aliskiren: A Novel, Orally Active Renin Inhibitor." Systematic Reviews in Pharmacy 1.1 (2010), 93-98. Print. doi:10.4103/0975-8453.59518 APA (American Psychological Association) Style Mohamed Saleem TS, Jain A, Tarani P, Ravi V, Gauthaman K (2010) Aliskiren: A Novel, Orally Active Renin Inhibitor. Systematic Reviews in Pharmacy, 1 (1), 93-98. doi:10.4103/0975-8453.59518